Total costs, life-years and QALYs were Lt 141,166.76, 1.179 and 1.234 with PEG, Lt 114,482.41, 0.658 and 0.689 with interferon alpha, Lt 109,398.55, 0.423 and 0.442 with lamivudine for 48 weeks and Lt 123,876.51, 1.104 and 1.153 with lamivudine for five years.
In the cost-effectiveness analysis, incremental cost per life-year gained for PEG was Lt 51,256.92 (€14,845.03) compared to interferon alpha, Lt 41,993.67 (€12,162.21) compared to lamivudine for 48 weeks and Lt 230,229.69 compared to lamivudine for five years.
In the cost-utility analysis, incremental cost per QALY gained was Lt 48,980.08 (€14,185.61) with interferon alpha, Lt 40,096.19 (€11,612.66) with lamivudine for 48 weeks and Lt 214,785.71 with lamivudine for five years.
In the sensitivity analysis, incremental cost-effectiveness ratios with PEG ranged from Lt 24,412.64 to Lt 230,229.69 and incremental cost-utility ratios ranged from Lt 23,246.59 to Lt 214,785.71.